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Breast milk and in utero transmission 
of HIV-1 select for envelope variants 
with unique molecular signatures
Kyle J. Nakamura1,2, Laura Heath3, Edwin R. Sobrera1, Thomas A. Wilkinson1, Katherine Semrau4, 
Chipepo Kankasa5, Nicole H. Tobin6, Nicholas E. Webb6, Benhur Lee7, Donald M. Thea4, Louise Kuhn8, 
James I. Mullins3 and Grace M. Aldrovandi6*
Abstract 
Background: Mother-to-child transmission of human immunodeficiency virus-type 1 (HIV-1) poses a serious health 
threat in developing countries, and adequate interventions are as yet unrealized. HIV-1 infection is frequently initiated 
by a single founder viral variant, but the factors that influence particular variant selection are poorly understood.
Results: Our analysis of 647 full-length HIV-1 subtype C and G viral envelope sequences from 22 mother–infant pairs 
reveals unique genotypic and phenotypic signatures that depend upon transmission route. Relative to maternal 
strains, intrauterine HIV transmission selects infant variants that have shorter, less-glycosylated V1 loops that are more 
resistant to soluble CD4 (sCD4) neutralization. Transmission through breastfeeding selects for variants with fewer 
potential glycosylation sites in gp41, are more sensitive to the broadly neutralizing antibodies PG9 and PG16, and 
that bind sCD4 with reduced cooperativity. Furthermore, experiments with Affinofile cells indicate that infant viruses, 
regardless of transmission route, require increased levels of surface CD4 receptor for productive infection.
Conclusions: These data provide the first evidence for transmission route-specific selection of HIV-1 variants, 
potentially informing therapeutic strategies and vaccine designs that can be tailored to specific modes of vertical HIV 
transmission.
Keywords: HIV-1, Mother-to-child transmission, Envelope, CD4, Glycosylation, Broadly neutralizing antibodies
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite focused efforts upon preventative measures, 
pediatric human immunodeficiency virus-type 1 (HIV-
1) infections through mother-to-child transmission 
(MTCT) continue to challenge clinicians and strain 
healthcare systems, with 1.5 million HIV-positive women 
giving birth and 240,000 children acquiring the virus in 
2013 [1]. HIV-1 MTCT can occur through three dis-
tinct routes: in utero (transplacental passage), intrapar-
tum, and postpartum through breastfeeding. Studies of 
HIV-infected infants indicate that disease progression 
can vary dramatically among these transmission modes, 
with infants infected in utero showing the shortest times 
of survival [2, 3]. An understanding of the genotypic and 
phenotypic factors that uniquely distinguish these routes 
of HIV transmission is crucial for developing targeted 
preventative strategies including vaccines.
A large majority of HIV-1 infections that occur through 
sexual or vertical transmission are established by a sin-
gle “founder” variant, with primary infection being char-
acterized by a virus population with significantly less 
sequence diversity compared to donor viruses [4–17]. 
The founding variant(s) typically utilize the chemokine 
receptor CCR5 for entry, and may represent a minority 
population from the donor [4, 8–10, 14, 18–22]. Stud-
ies of heterosexual transmission (subtypes A, C and D) 
Open Access
Retrovirology
*Correspondence:  GAldrovandi@mednet.ucla.edu 
6 Division of Pediatric Infectious Diseases, Department of Pediatrics, David 
Geffen School of Medicine at the University of California at Los Angeles, 
Los Angeles, CA, USA
Full list of author information is available at the end of the article
Page 2 of 19Nakamura et al. Retrovirology  (2017) 14:6 
[5, 18, 23, 24] and of MTCT (subtype CRF01_AE) [12] 
have identified certain “molecular signatures” in founder 
variants, such as shorter envelope variable loops, loss 
of potential N-glycosylation sites (PNGs), or selection 
of particular PNGs in transmitted strains, but no such 
signatures have been observed following transmission 
of subtype B variants [23, 25, 26]. Although previous 
MTCT studies had limitations of small sample size, a lim-
ited focus to specific regions within the envelope, and/
or the inability to discriminate between different routes 
of MTCT [4, 6, 7, 9, 12, 13, 27–33], all of these studies 
reported detection of a single or few founder variants. 
Some (but not all) MTCT studies have reported genetic 
differences between viral strains transmitted in utero 
and intrapartum [6, 12, 34]. Investigations of the role of 
maternal neutralizing antibodies in shaping the founder 
virus population during MTCT have yielded conflict-
ing results: while some data show that selected founder 
viruses represent maternal antibody escape variants [30, 
34], other studies find no such relationship [32].
As the major viral protein assembly on the virion sur-
face, the HIV envelope protein spike holds the dual dis-
tinction of being both the ‘key’ that the virus uses to 
unlock susceptible target cells in the exposed infant as 
well as being the primary target of neutralizing antibod-
ies. The HIV-1 envelope spike assembly is composed of 
a trimer of glycosylated gp120/gp41 heterodimers, and is 
responsible for mediating entry into host cells via interac-
tions with the CD4 receptor and a co-receptor (typically 
CCR5). The gp120 subunit lies entirely on the extracellu-
lar surface, while the standard envelope topology model 
describes gp41 as having an extracellular domain, a single 
membrane-spanning domain, and a cytoplasmic domain 
(CD) [35]. Analysis of gp120 sequences from diverse 
viral strains identifies five regions of high sequence vari-
ability (variable domains V1–V5) interspersed within five 
relatively constant domains (C1–C5) [36, 37] (Additional 
file  1: Figure S1). The tremendous sequence diversity 
within the gp120 variable regions enables escape from 
neutralizing antibodies [38]. In addition to CD4 and 
CCR5, the gp120 subunit can engage other cell-surface 
proteins that may facilitate mucosal transmission, such 
as dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin (DC-SIGN) [39] and the integrin 
α4β7 [40, 41]. Envelope recognition of the CD4 receptor, 
co-receptor, and other key cell surface proteins, all while 
simultaneously escaping antibody surveillance, suggests 
functional sequence constraints that govern the selection 
of the founding variant(s) from the swarm of donor iso-
lates during transmission.
MTCT differs significantly from other HIV transmis-
sion modes: first, MTCT occurs in the presence of mater-
nal antibodies to HIV, with infant levels of maternal 
antibodies being greater than or equivalent to those in 
the mother at birth, and then decreasing over the first 
few months of life [42]. Second, the infant immune sys-
tem differs in the quantity, distribution, and activation 
state of CD4+ T cells compared to adults [43]. Third, 
infants share half their genetic identity with their moth-
ers, leading to greater immunologic overlap between 
donor and recipient than occurs during sexual or par-
enteral transmission. Moreover, MTCT in utero, intra-
partum and through breastfeeding each involves unique 
physical exposures, biological barriers, and developmen-
tal states of the infant that could influence transmission 
dynamics and founding strain selection. Given such dis-
tinctive transmission features, as well as the critical role 
of HIV envelope protein in establishing infection and 
escaping the host immune system, we performed a large, 
systematic analysis of the genetic and phenotypic proper-
ties of HIV envelope variants transmitted from mother to 
child by different routes, with the aim of identifying viral 
characteristics that might confer selective advantages for 
mode-specific transmission.
Results
Transmission timing and phylogenetic linkage of HIV 
strains within mother‑to‑child transmission pairs
We examined 22 MTCT pairs participating in the Zam-
bia Exclusive Breastfeeding Study (ZEBS) [44]. Six moth-
ers from this cohort transmitted in utero (IUT), as their 
infants were HIV-positive at birth by PCR tests, while 
13 mothers transmitted virus through breastfeeding 
(BMT), since their infants were HIV-negative at birth and 
at 1 month of age, but HIV-positive after 42 days. Three 
mothers were classified as “indeterminate” transmitters 
(IND), as their infants were HIV-negative at birth but 
HIV-positive after 1  month: as such, the precise timing 
of when these infants acquired virus (either postpartum 
or during labor and delivery) is unclear. To confirm trans-
mission linkage, we cloned, sequenced and compared 
647 envelope genes following polymerase chain reaction 
(PCR) amplification. In all, we obtained 245 envelope 
sequences from infants from the first available HIV-1 
PCR-positive infant blood sample, and 402 sequences 
from mothers (Fig.  1). Envelope sequences of mater-
nal origin were typically taken from maternal blood and 
breast milk samples collected either at study entry (for 
IUT and IND pairs) or from maternal samples collected 
within ~35  days prior to the infant’s first positive PCR 
test (for BMT pairs) (Table  1). In all, we obtained 228 
envelope sequences from the IUT group, 365 sequences 
from the BMT group, and 54 sequences from the IND 
group (Fig. 1). From within the IUT group, 162 envelope 
sequences were amplified from blood samples and 66 
from milk, while from within the BMT group 309 and 56 
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envelope sequences were obtained from blood and milk 
samples, respectively (Table  2). When gp160 sequences 
from the entire cohort were placed into a phylogenetic 
tree, each transmission pair formed a monophyletic clus-
ter, with infant envelope sequences forming a sub-cluster 
within each larger maternal cluster (Fig.  2a). From this 
analysis, we determined that 21 transmission pairs were 
infected with subtype C virus, while one pair (Pair 8 from 
the BMT group) was infected with HIV-1 subtype G 
(Fig. 1).
Founder populations and reduction in viral diversity 
upon mother‑to‑child transmission
Envelope amino acid sequences obtained from infant 
samples were significantly less diverse than mater-
nal sequences (Fig.  2b), but did not differ significantly 
in gp160 length (mean of 858.2 residues for all infant 
strains in the cohort, and 857.4 residues for the mater-
nal strains; p =  0.760) or in number of PNGs (mean of 
29.6 and 28.7 PNGs for infant and maternal strains, 
respectively; p  =  0.192), as determined by comparison 
of means derived from generalized estimating equations 
(GEE) modeling (Fig. 3a, b). The number of founder vari-
ants establishing infection was judged by analyzing phy-
logenies, viral diversity, insertion and deletion patterns 
(indels) and the number and linkage of phylogenetically 
informative mutations in each infant’s virus population 
(see Additional file 10: Table S1; Additional file 2: Figures 
S2, Additional file 3: Figure S3). At least 12/22 infections 
(9/13 BMT, 2/6 IUT, and 1/3 IND) were consistent with 
a single founder variant. The incidence of putative multi-
founder infections was lower in the BMT group than in 
the IUT group (31% of breast milk transmissions vs. 67% 
of in utero transmissions), but this difference was not sta-
tistically significant (p = 0.319, Fisher’s exact test).
Distinct envelope protein characteristics of maternal 
and infant virus variants
All infant variants used CCR5 for entry, as determined 
from infection assays using pseudotyped HIV virions 
bearing the infant envelope sequences and TZM-bl cells 
in the presence of high TAK-779 concentrations, and/or 
from infection of GHOST cells co-expressing CD4 and 
either CCR5 or CXCR4 (data not shown).
To determine if a critical set of epitopes within HIV-1 
envelopes are being selected during MTCT in this 
cohort, we tested a broad array of envelope-specific 
inhibitors in infection assays against pseudotyped HIV-1 
virions bearing viral envelopes of either infant or mater-
nal origin. These inhibitors included broadly neutralizing 
monoclonal antibodies (bnAbs) such as the V1/V2 loop-
specific PG9 and PG16 [45–47]; 2F5 and 4E10, which 
bind to the membrane-proximal external region (MPER) 
of gp41 [48–51]; 2G12, which recognizes carbohydrate 
Fig. 1 Mosaic plots showing groupings by subject (maternal or infant), transmission mode, and transmission pair ID number for the 647 infant- and 
maternal-derived envelope clones obtained in this study. The number of envelope variants represented within each group is indicated inside each 
tile. IUT, in utero transmission; BMT, breast milk transmission; IND, indeterminate transmission mode. Twenty-one transmission pairs were infected 
with HIV-1 subtype C, while one pair (Pair 8, shown in green) was infected with subtype G
Page 4 of 19Nakamura et al. Retrovirology  (2017) 14:6 
moieties on the outer domain of gp120 [48, 52, 53]; and 
b12, which targets a CD4 binding epitope on gp120 
[54–58]. We also tested the inhibitory activities of solu-
ble sCD4 (a 26  kDa protein) [59], the small molecule 
CCR5 inhibitor TAK-779 [60, 61], and the 36-amino acid 
fusion inhibitor enfuvirtide (T-20) [62], which we used to 
probe HIV-1 envelope interactions with the CD4 recep-
tor, the CCR5 co-receptor, and the envelope capacity to 
trigger membrane fusion, respectively. These experi-
ments allowed (a) probing of neutralization sensitiv-
ity using standardized reagents, (b) examination of the 
accessibility of specific neutralizing epitopes (e.g., the 
gp41 MPER), and (c) assessment of the potential useful-
ness of available bnAbs in the setting of MTCT (either as 
a prophylactic intervention or a vaccine template).
In all, we performed inhibition assays with 322 dif-
ferent envelopes from this cohort: 223 obtained from 
maternal samples and 99 from infant samples. Suscepti-
bility to the bnAbs 4E10, 2F5, b12, 2G12, and T-20 was 
similar between infant and maternal variants (data not 
shown). Infant variants also showed similar susceptibility 
as the maternal variants to PG16 (p = 0.150) and TAK-
779 (p = 0.429), but were more sensitive to PG9 (mean 
IC50 of 0.17  µg/mL for infant strains and 0.38  µg/mL 
for maternal strains; p = 0.035) and more resistant than 
the maternal variants to sCD4 (mean IC50 of 13.7  µg/
mL for infant strains and 8.8 µg/mL for maternal strains; 
p = 0.0007) (Fig. 3c–f). When the data were stratified by 
route of transmission, a unique transmission signature 
Table 1 Clinical data for the 22 maternal–infant pairs in the cohort
Route of transmission Maternal–infant  
pair ID
Maternal HIV RNA  
(copies/mL of plasma)
Maternal CD4+ count  
(cells/nL)
Time between infant 
and maternal sample  
collection (days)
BMT 1 300,000 76 158
BMT 2 200,656 154 240
BMT 3 206,763 94 143
BMT 4 50,291 332 205
BMT 5 298,310 110 35
BMT 6 143,217 276 35
BMT 7 270,691 317 31
BMT 8 117,007 103 28
BMT 9 104,209 198 32
BMT 10 509,607 300 37
BMT 11 83,060 137 35
BMT 12 45,907 52 35
BMT 22 43,301 88 38
Median 143,217 137 35
IUT 13 39,801 138 91
IUT 14 375,319 94 99
IUT 15 18,220 246 350
IUT 16 211,792 118 191
IUT 17 47,602 291 36
IUT 23 537,736 318 183
Median 129,697 192 141
IND 18 750,001 91 227
IND 19 358,315 219 132
IND 20 6855 299 140
Median 358,315 219 140
Table 2 Number of  envelope sequences obtained 
from  either blood or milk samples, grouped by  transmis-
sion mode
IUT in utero transmission, BMT transmission through breastfeeding, IND 
indeterminate (timing of HIV transmission unclear)
Route of transmission Source of env sequences
Blood Milk
IUT 162 66
BMT 309 56
IND 53 1
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was identified for each route, as described below. To 
better examine genotypic and phenotypic differences in 
strains having precisely defined modes of transmission, 
we focused our analysis on strains solely from the IUT 
and BMT groups, and did not explore further the enve-
lope variants from the IND group.
Fig. 2 Genetic analysis of HIV envelope sequences among MTCT pairs. a Phylogenetic tree of all 22 mother–infant transmission pairs included in 
study. All maternal envelopes form distinct phylogenetic clusters, with infant envelopes forming a subcluster within the larger maternal cluster. 
Infant envelopes are colored differently from the maternal envelopes (often in a lighter shade). b Comparison of infant versus maternal envelope 
diversity was performed using the approach described by Gilbert et al. [104] for comparing genetic distances. Infant envelopes (shown on the left) 
were significantly less diverse than maternal envelopes (p < 0.001)
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‘Transmission signatures’ of in utero and breast milk 
infection
Genotypic characteristics
In contrast to the overall comparisons between mater-
nal and infants viruses described above, when stratified 
by transmission route, in utero transmission selected for 
gp160 variants that were shorter (mean length of 852.0 
residues in infant variants and 857.6 in maternal vari-
ants; p = 0.008) and encoded fewer PNGs (mean of 27.8 
sites in infant variants and 29.7 in maternal variants; 
p = 0.001) (Fig. 4a, b). When such analyses were confined 
to the V1–V4 region for the IUT group, the infant enve-
lope variants had shorter V1–V4 lengths than maternal 
variants (mean of 277.0 residues in infant strains and 
282.7 residues in maternal strains; p = 0.001) and fewer 
PNGs (mean of 18.8 sites within V1–V4 in infant strains, 
and 20.7 sites in V1–V4 of maternal strains; p = 0.001). 
This observed decrease in V1–V4 length and number of 
PNGs is similar to that encountered in studies of hetero-
sexual transmission of HIV-1 subtype C [5], but neither 
was detected in our breast milk transmission group.
Examination of each individual variable and constant 
domains (V1–V5 and C1–C5) indicated that infant 
variants within the IUT group had shorter V1 loops 
than those found in their maternal counterparts (mean 
V1 length of 20.1 residues in infant isolates and 24.1 
residues in maternal isolates; p  =  0.001). Strains from 
infected infants also had fewer V1 PNGs (mean of 2.4 
sites in infant isolates and 3.0 sites in maternal isolates; 
p = 0.017) and fewer V5 PNGs (mean of 1.2 sites in infant 
isolates and 1.5 sites in maternal isolates; p  =  0.017) 
(Fig. 4c). No differences in length or number of PNGs for 
gp160, V1–V4, or V1 regions were observed in the BMT 
group (Fig. 4d). Infant isolates from the BMT group had 
fewer PNG sites only within gp41 (mean of 3.9 PNGs in 
gp41 of infant strains and 4.3 PNGs in gp41 from mater-
nal strains; p = 0.017), while no such difference in gp41 
PNGs was observed in the IUT group.
a b
c d
e f
Fig. 3 Aggregate analysis of HIV envelope proteins from the 22 
transmission pairs included in this study. GEE-derived p values indi-
cate whether genotypic and phenotypic parameters are significantly 
different between infant and maternal groups, with p values ≤0.05 
shown in red. The gray box indicates the 95% confidence interval and 
the whiskers indicate the 99% confidence interval. a Comparison of 
gp160 length (in number of amino acids) for all maternal and infant 
envelopes. b Comparison of gp160 glycosylation level (in number 
of PNG motifs) for maternal and infant envelopes. c–f Comparison 
of the mean 50% inhibitory concentration (IC50) of c PG9, d PG16, 
e TAK-779, and f sCD4 against envelopes from maternal and infant 
isolates. The number of envelope sequences tested for each group (n) 
is also shown
(See figure on next page.) 
Fig. 4 Genotypic signature for IUT and BMT groups. a Comparison of gp160 length (in number of amino acids) and b glycosylation level (in num-
ber of PNGs) for maternal and infant envelopes, segregated by route of transmission. The number of envelope sequences tested for each group (n) 
is given. c–d Comparison of infant and maternal envelope sequence length and PNG content, stratified by transmission mode and by gp120 vari-
able domains (V), constant domains (C), and the gp41 subunit. Each bar along the horizontal axis represents an individual transmission pair, which 
is solid if comparison between the individual mother–infant pair is significant (p < 0.05) and outlined if not significant*. The y-axis represents either 
the difference in sequence length or the difference in number of PNG sites found between infant and maternal envelope clones, computed as 
[mean maternal isolate length (or PNG content)—the mean infant isolate length (or PNG content)] for each pair. p values were calculated using GEE 
for each individual domain, and domains that differed significantly for corresponding maternal and infant isolates are boxed in red. The graph in c 
shows differences in sequence length and PNG level for in utero transmission pairs, and d shows differences in length and PNG level for breast milk 
transmission pairs. *Wilcoxon rank-sum tests were used to compare sequence length or PNG content found in maternal and infant isolates from a 
given transmission pair, with resulting p values being corrected for multiple comparisons using the method of Benjamini and Hochberg [105]
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Inhibitor IC50 comparison
In utero transmission failed to select infant-derived vari-
ants that differed significantly in bnAb sensitivity from 
maternal-derived variants, or in sensitivity to the inhibi-
tors TAK-779 (Fig. 5) and T-20 (data not shown). How-
ever, GEE analysis of the mean sCD4 IC50’s showed that 
infant-derived variants from the IUT group were more 
resistant to sCD4 than corresponding maternal variants 
(mean sCD4 IC50 of 12.3  µg/mL for virus with infant-
derived envelopes and 6.2 µg/mL for virus with maternal-
derived envelopes; p = 0.0002) (Fig. 5). We further noted 
that when confining comparisons to within mother–
infant pairs, the infant isolates showed higher median 
sCD4 IC50 values than those seen for corresponding 
maternal isolates in 5/6 IUT pairs (Additional file 4: Fig-
ure S4a). However, no statistically-significant difference 
in sCD4 IC50 for maternal and infant isolates within any 
given IUT mother–infant pair was confirmed (as deter-
mined by Wilcoxon rank-sum tests, followed by p value 
correction for multiple comparisons), perhaps owing to 
the relatively small number of envelopes being examined 
within each mother–infant pair. No difference in mean 
sCD4 sensitivity between infant- and maternal-derived 
isolates was observed in the BMT group, either in the 
aggregate or on a pair-by-pair basis (Additional file  4: 
Figure S4b).
Within the BMT group, infant variants were more 
susceptible than maternal variants to neutralization 
by bnAbs PG9 (mean IC50 of 0.16 µg/mL for virus with 
infant-derived envelopes and 0.68  µg/mL for virus with 
maternal-derived envelopes; p  =  0.0004) and PG16 
(mean IC50 of 0.04  µg/mL for virus with infant-derived 
envelopes and 0.21  µg/mL for virus with maternal-
derived envelopes; p  =  0.013), a difference that is not 
observed in the IUT group (Fig.  5). When comparing 
within BMT mother–infant pairs, the infant variants 
showed lower median PG9 and PG16 IC50 values than 
the corresponding maternal variants in 8/13 pairs (Addi-
tional file 4: Figure S4b). Using Wilcoxon rank-sum tests, 
no statistically significant differences in PG9 or PG16 
IC50 values for the maternal and infant isolates within any 
of the BMT pairs were discerned, though this analysis 
a b
c d
Fig. 5 Phenotypic differences between variants transmitted in utero and through breast milk. Mean inhibitor IC50 values by subject and transmis-
sion mode were obtained through GEE calculations. The grey box indicates the 95% confidence interval and the whiskers indicate the 99% confi-
dence interval. p values showing significant inhibitor IC50 differences for infant- and maternal-derived strains are indicated in red. Inhibitors tested 
were a TAK-779, b sCD4, c PG9, and d PG16. The number of envelope sequences tested for each group (n) is shown
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may have been limited by the relatively low number of 
isolates analyzed within each BMT pair.
CD4 usage
In utero MTCT may depend upon initial infection of pla-
cental macrophages (e.g., Hofbauer cells), which have low 
surface densities of CD4 molecules [31, 63, 64]. To fur-
ther explore the CD4 usage phenotype in our cohort, we 
investigated whether infant- and maternal-derived enve-
lopes productively engage CD4 with differing efficiencies, 
and whether any difference in CD4 usage depends upon 
route of transmission. Towards this end, we used Affino-
file cells [65] to test viral entry properties of 151 molecu-
lar envelope clones obtained from the 6 IUT and 11 of 
the 13 BMT pairs in our cohort (10 BMT pairs infected 
with HIV-1 subtype C and 1 with subtype G).
Affinofile cells can be induced to express varying lev-
els of surface CD4 in a controllable fashion, allowing for 
standardized and reproducible infection of cells across a 
wide, physiologically-relevant range of CD4 surface den-
sities. Affinofile cells were treated with ponasterone to 
maximally induce CCR5 expression, followed by addition 
of varying doses of doxycycline to yield controlled levels 
of CD4 expression. Infectivity curves were constructed 
by varying CD4 expression/cell over a 100-fold range, 
infecting cells with 2000 infectious units of virus pseu-
dotyped with either infant or maternal envelope vari-
ants, and subsequently determining for each variant the 
number of CD4 molecules/cell (expressed as the number 
of α-CD4 antibody binding sites (ABS)/cell) required to 
achieve 20% of maximal entry (EC20). Analysis of EC20’s 
showed that infant-derived variants from the IUT group 
required more CD4 molecules than their maternal coun-
terparts (mean EC20 of 4596 ABS/cell for virus with 
infant-derived envelopes and 3817 ABS/cell for virus 
with maternal-derived envelopes; p  <  0.0001) (Fig.  6, 
Additional file  5: Figure S5). Pseudotyped virions from 
the BMT group showed similar behavior: infant vari-
ants in the BMT group required more CD4 molecules to 
achieve 20% of maximal entry than corresponding mater-
nal strains (mean EC20 of 4409 ABS/cell for infant strains 
and 3387 ABS/cell for maternal variants; p  =  0.001) 
(Fig. 6, Additional file 5: Figure S5). These results indicate 
that envelopes from the infant-derived strains in both 
IUT and BMT groups use CD4 less efficiently than cor-
responding maternal strains, as the infant strains require 
more CD4 molecules than their maternal counterparts 
to achieve comparable levels of target cell infection. 
Additionally, we evaluated CCR5 usage in a small sub-
set of mother–infant pairs, 2 IUT and 4 BMT. Despite 
the small numbers, infant variants in the IUT group did 
require less CCR5 molecules for entry than correspond-
ing maternal strains (mean EC20 of 411 α-CCR5 antibody 
binding sites (ABS)/cell) required to achieve 20% of max-
imal entry (EC20ABS/cell for infant strains and 493 ABS/
cell for maternal variants; p  <  0.001) (Additional file  6: 
Figures S6, Additional file  7: Figure S7). This difference 
was not seen in the BMT group (mean EC20 of 370 ABS/
cell for infant strains and 553 ABS/cell for maternal vari-
ants; p = 0.153) nor when all 6 subjects were evaluated 
together (Additional file  6: Figures S6, Additional file  7: 
Figure S7).
Dose–response curve analysis
To further understand inhibition mechanisms for HIV-1 
neutralization, and to ascertain functional differences in 
virions that are transmitted either in utero or through 
breast milk feeding, we fit inhibition curves of PG9 and 
sCD4 to the median effect model [66, 67]. In the median 
effect model, the slope parameter (m) provides a measure 
of allosteric cooperativity in inhibitor binding for multi-
valent targets, such as the HIV Env trimer. Slopes greater 
than 1 (m > 1) indicate positive cooperativity, where the 
binding of one inhibitor molecule to an Env spike allos-
terically increases the affinity of other binding sites on 
the trimeric Env. This favors the binding of additional 
inhibitor molecules and results in a steep dose-depend-
ent rise in inhibitor activity and a high slope. Slopes less 
than 1 (m  <  1) indicate negative cooperativity, where 
the inhibitor allosterically decreases the affinity of other 
binding sites, resulting in a shallow rise in inhibition and 
a low slope. Slopes equal to 1 (m = 1) indicate non-coop-
erativity, where an inhibitor has no allosteric effects on 
the Env structure.
Fig. 6 Surface CD4 molecules needed to produce 20% of maximum 
infectivity (EC20), by subject and transmission type. The number of 
envelope sequences tested for each group (n) is shown. The grey box 
indicates the 95% confidence interval and the whiskers indicate the 
99% confidence interval
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Mean slope parameters obtained for PG9 against 
infant-derived and maternal-derived virions were both 
<1 and not significantly different from one another, either 
within the IUT or within the BMT groups (Additional 
file 8: Figure S8). Mean slope parameters for sCD4 inhi-
bition of infant and maternal variants were also <1, and 
not significantly different within IUT group (mean slope 
of 0.59 for infant isolates and 0.68 for maternal isolates 
within the IUT group; p = 0.345) (Fig. 7). However, the 
sCD4 slopes for infant isolates in the BMT group were 
significantly lower than their maternal counterparts 
(mean slope of 0.52 for infant isolates and 0.76 for mater-
nal isolates within the BMT group; p  =  0.0003) (Addi-
tional file  9: Figure S9). Slopes that are <1, as seen in 
these sCD4 inhibition experiments, suggest that binding 
of an initial sCD4 molecule discourages binding of addi-
tional sCD4 molecules to the trimeric HIV-1 spike com-
plex. Such behavior is characteristic of sCD4 inhibition 
for infant and maternal variants in both IUT and BMT 
groups in this cohort, and this negative cooperativity 
becomes more pronounced in the infant isolates from the 
BMT group relative to their maternal counterparts.
Discussion
Our detailed investigation of viral isolates obtained 
from maternal–infant transmission pairs revealed that 
genotypic and phenotypic features of HIV-1 envelopes 
acquired in utero (transplacental transmission) can be 
clearly distinguished from those acquired from breast 
milk (mucosal transmission). In utero transmission 
selects for HIV-1 subtype C infant isolates with shorter, 
less-glycosylated envelopes: specifically, the V1 domain 
of in utero-acquired envelope sequences is shorter, and 
the V1 and V5 domains contain fewer PNGs than cor-
responding maternal isolates. These observations sug-
gest that envelopes with more compact V1 domains and 
less-glycosylated V1 and V5 domains impart a selective 
advantage to virions in establishing in utero infections. 
A recent study shows that HIV-1 subtype C isolates 
with compact V1/V2 regions have enhanced fusion effi-
ciency and envelope incorporation into virions [68], and 
therefore the shorter V1 region within in utero-acquired 
strains in our present study may confer improved viral 
fusion kinetics and envelope uptake, potentially a basis 
for selection during intrauterine transmission. In con-
trast, breast milk transmission selects for HIV-1 variants 
that do not differ in overall length or glycosylation from 
maternal variants, but have fewer PNG sites in gp41, and 
are more sensitive to neutralization by the bnAbs PG9 
and PG16. These particular genotypic and phenotypic 
signatures are unique to either intrauterine or breast milk 
transmission, but not both (Fig. 8).
Placental macrophages represent a population of HIV-
susceptible fetal cells in close proximity to the maternal 
circulatory system, and express relatively low amounts 
of CD4 [63]. Previous work suggests that a higher affin-
ity for CD4 correlates with increased susceptibility to 
sCD4 [69]. We therefore hypothesized that infection of 
placental macrophages would require variants with high 
CD4 affinity to scavenge the relatively scarce amounts 
of available CD4, and anticipated that envelope isolates 
from in utero-infected infants would thus be more sensi-
tive to sCD4 inhibition. Contrary to our expectation, our 
data indicate that infant strains that emerged following in 
utero transmission display weaker interactions with the 
CD4 receptor and a lower binding affinity than mater-
nal strain counterparts. Infection assays with TZM-bl 
cells show that infant envelope variants from the IUT 
group have an approximately twofold higher mean sCD4 
IC50 value than that of corresponding maternal variants. 
These findings suggest that these infant-derived enve-
lopes bind to cognate CD4 receptors on the cell surface 
with lower affinity than those from paired maternal iso-
lates. In addition, our experiments with Affinofile cells 
show that all infant isolates require more surface CD4 
than their maternal counterparts to achieve comparable 
levels of target cell infection. These data indicate that 
the transmitted infant variants exhibit a decreased CD4 
usage efficiency reflected by both a decreased affinity and 
a higher stoichiometric requirement for entry. Conceiv-
ably, despite having lower CD4 affinity these infant enve-
lope variants may have high CD4 avidity to achieve tight 
CD4 binding in this setting, exploiting interactions of 
multiple trimeric spike protein subunits with clusters of 
CD4 receptors in a contact zone (a so-called “entry claw”) 
[70, 71] to successfully attach to and infect target cells. 
Fig. 7 Comparison of median effect sCD4 slopes by subject and 
transmission mode. The number of envelope sequences tested for 
each group (n) is shown
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Here, an elevated CD4 surface density promotes high 
HIV-1 envelope-CD4 avidity and ensuing infection. One 
additional possibility that is consistent with our sCD4 
data is that the target fetal cells initially infected during 
in utero transmission actually express a relatively higher 
amount of CD4, which may result if a transient inflam-
matory process occurs during gestation, resulting in 
elevated CD4 expression and facilitating MTCT despite 
transmitted isolates having a relatively low CD4 affinity.
Alternatively, in utero-transmitted isolates with weak-
ened CD4 affinity might actually possess a reduced 
reliance upon CD4, perhaps by assuming envelope con-
formations that are predisposed to immediate CCR5 
engagement. In an infection model that requires little 
CD4, a reduced CD4 affinity would pose no great fit-
ness penalty: conceivably, any additional surface CD4 
density beyond a certain threshold level could help pro-
mote infection, but this excess CD4 would not be strictly 
required. Our dose–response curve analysis of the sCD4 
inhibition data using the median effect framework [67] 
is consistent with this later interpretation. The mean 
sCD4 slope parameter for in utero-transmitted infant 
variants, though not significantly different from that of 
paired maternal variants, is <1 (mean slope of ~0.6). This 
low slope parameter suggests that initial envelope trimer 
engagement of a CD4 molecule discourages subsequent 
binding of additional CD4 molecules (i.e., negative coop-
erativity), perhaps by the envelope adopting a conforma-
tion that occludes or disturbs the remaining CD4 binding 
sites on the trimer. Such a conformation might confer 
a selective advantage by better exposing the CCR5 co-
receptor binding site, providing easier access for CCR5 
co-receptor and relying less upon the usual CD4 bind-
ing event(s) to engage CCR5 and subsequently trigger 
viral fusion. The low slope parameter observed in our 
study might also imply slower envelope activation kinet-
ics, which would provide additional time to assemble an 
entry-competent complex with co-receptor following an 
initial CD4 binding event.
While most HIV-1 isolates are CD4-dependent, some 
variants with low or no requirement for CD4 have 
been described (reviewed in Ref. [72]). Brain-derived, 
Fig. 8 Genotypic and phenotypic features of HIV-1 isolates acquired in utero are distinct from those acquired through breastfeeding. On the far 
left, the pool of viral variants present in the chronically-infected donor are represented by differently-colored virion cores, with heavily-glycosylated 
envelopes coated in blue and those with less glycosylation coated in red. Strong selection during or following transmission (red box, middle) results 
in either a single or a very small number of variants that ultimately establish acute infection in the new host (right). Genotypic and phenotypic sig-
natures by route of MTCT are as shown. For subtype C variants, heterosexual transmission bears similarity to transmission in utero, as both transmis-
sion modes select for isolates with shorter and less-glycosylated variable regions. MTCT of HIV-1 takes place in the presence of HIV-specific maternal 
antibody, while heterosexual transmission does not
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macrophage-tropic HIV-1 envelope variants with low 
CD4 requirements and increased fusogenicity have 
been isolated [73], and macrophage tropism of simian 
immunodeficiency virus (SIV) is associated with CD4 
independence [74, 75] and reduced CD4 affinity [76]. 
In addition, data from other Affinofile cell experiments 
suggest that HIV-1 macrophage tropism requires lit-
tle CD4 (but is not completely CD4-independent) [77]. 
Given our data and observations from studies described 
above, we surmise that selective pressures during in utero 
transmission yield infant isolates with low CD4 require-
ments for productive infection, and that are well-poised 
to infect placental macrophages (e.g., Hofbauer cells) that 
have lower cell surface CD4 densities, perhaps through 
exploiting higher CD4 avidity, direct co-receptor binding, 
and/or having enhanced fusogenic properties.
Our studies provide other insights into factors that 
select the HIV variants that establish infection. Replica-
tion of viral lineages that are genetically distinct from 
those circulating in the blood can be found within the 
central nervous system [78, 79], in the genital tract [80], 
and within the placenta [31]. Conversely, we and oth-
ers have previously shown that virus found in maternal 
blood and in breast milk and are not genetically distinct 
from one another [81–84], suggesting that the observed 
genetic restriction during BMT must occur within recipi-
ent infant tissues, perhaps involving specific cellular 
factors.
HIV variants from infants infected in utero in our 
study were similar to those described in heterosexual 
transmission of HIV-1 subtypes A and C [5, 23], i.e., hav-
ing shorter variable loops with fewer PNGs than those 
found in the transmitting partner. The finding that vari-
ants that traverse the placenta have similar genotypic 
characteristics to those that breach the male and female 
genital tracts suggests that these different anatomical 
compartments impose common selective pressures that 
favor (in each setting) transmission of virions with more 
compact envelope variable regions having fewer PNGs 
(Fig.  8). Although the origin of such selective pressures 
is currently unknown, candidates under consideration 
include cellular lectins (reviewed in Ref. [85]), whose 
presence could potentially favor transmission of under-
glycosylated envelope isolates that can escape the innate 
immune system, or the cellular integrin α4β7, which may 
facilitate mucosal transmission through strong interac-
tions with less-glycosylated V1/V2 regions [86]. Finally, 
a strong requirement for virions with elevated envelope 
incorporation and efficient viral fusion properties dur-
ing heterosexual and in utero transmission might lead to 
the selection of isolates having compact V1/V2 regions, 
which have previously been shown to display this pheno-
type [68].
Unlike other forms of HIV transmission, MTCT occurs 
in the presence of HIV specific antibody. At birth, IgG 
antibody levels in the infant are equal or greater than 
those in the mother, but rapidly decline during the first 
few months of life [42, 87]. Although some studies indi-
cate that founder variants in infants have escaped mater-
nal neutralizing antibody [30], other studies have shown 
that neither breadth nor potency of passively acquired 
maternal antibody protect against breast milk transmis-
sion [88] and that maternal antibody does not strongly 
influence founder selection [32]. Nevertheless, the 
search for broadly neutralizing antibodies (bnAbs) that 
can serve either as a basis for vaccine design or as pas-
sively-administered therapeutics remains an active area 
of research [89]. The increased susceptibility to PG9 and 
PG16 of subtype C and G isolates from infants infected 
through breast milk in our study is consistent with obser-
vations from a previous report, which also showed that 
variants from infants infected through breast milk are 
sensitive to PG9 and PG16 [33]. In addition, subtype 
CRF01_AE isolates from infants infected perinatally also 
display increased PG9 and PG16 sensitivity over corre-
sponding maternal strains [90]. Collectively, these find-
ings support the exploration of bnAbs such as PG9 and 
PG16 in MTCT clinical trials.
Conclusions
In summary, our data indicate that different MTCT 
routes select genotypically and phenotypically distinct 
viral variants. These findings may have implications for 
both HIV pathophysiology and the development of suc-
cessful MTCT intervention strategies. Past studies sug-
gest that infants infected perinatally experience more 
rapid disease progression than those infected later by 
breastfeeding, with the accelerated pathogenesis being 
attributed to differences in immunologic maturity at the 
time of infection, and/or to detrimental effects of HIV 
infection upon infant growth and development [91, 92]. 
Alternatively, our data suggest that characteristic viral 
isolates for each transmission setting might infiltrate tar-
get tissues through unique mechanisms that may con-
tribute to the observed differences in disease progression. 
Further comparison analyses of the HIV strains that are 
selected by different MTCT routes could elucidate these 
mechanisms, as well as lead to new therapeutic strategies 
or vaccine designs aimed at blocking vertical transmis-
sion in a mode-specific fashion.
Methods
Subjects
We selected 22 women who were enrolled in the Zambia 
Exclusive Breastfeeding Study (ZEBS) [44] and who were 
HIV-positive and pregnant at the time of enrollment. The 
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mothers and infants in our study population received a 
single-dose of nevirapine peripartum, as per Zambian 
government guidelines at the time of study enrollment. 
Infants were also given cotrimoxazole prophylaxis from 
6  weeks to 12  months of age [44]. The mode of viral 
transmission for each mother–infant pair was deter-
mined by the timing of the first HIV-1 PCR-positive test 
for the infant: infants who were showed a PCR-positive 
test at birth were deemed to have acquired virus in utero 
(n  =  6), while those infants who were PCR-negative 
at birth and at 1  month of age but PCR-positive after 
42  days were considered to be infected through breast-
feeding (n  =  13). Infants whose HIV-1 PCR tests were 
negative at birth but positive after 1 month were consid-
ered to have acquired virus either intrapartum or early 
postpartum (n = 3).
Envelope cloning
Peripheral blood and whole breast milk was collected at 
regular intervals starting at study enrollment (for maternal 
blood), and extending to 24 months post-delivery. Periph-
eral blood mononuclear cells (PBMCs) were separated by 
Ficoll–Hypaque centrifugation (MP Biomedicals) and pre-
served with RNAlater (Applied Biosystems) or DNAzol 
(Invitrogen), followed by freezing of both cells and cell-free 
plasma. Cell and supernatant/lipid fractions from breast 
milk were separated by centrifugation and then frozen.
Viral RNA copy numbers were determined from 
maternal plasma samples using the Roche Amplicor v1.5 
standard or ultrasensitive methods (Roche Diagnostics). 
Full-length gp160 sequences were amplified and cloned 
from either reverse-transcribed plasma RNA or from 
DNA extracted from PBMCs or breast milk cells using 
nested PCR with Vif1/OFM19 (outer) and EnvA/EnvN 
(inner) primer pairs, as previously described [5, 93]. 
Multiple independent PCR reactions were performed at 
or near limiting dilution (i.e. 0.1–10 template copies per 
reaction) to favor amplification of a single viral enve-
lope sequence. The env sequences from the 647 clones 
isolated in this cohort were obtained through bidirec-
tional Sanger sequencing, and initially analyzed using 
Sequencher (Genecodes), MacVector (MacVector Inc), 
and the LANL website tools (http://www.hiv.lanl.gov/
content/sequence/LOCATE/locate.html). Examination 
of env sequences proceeded as has been described pre-
viously [93]. In brief, all chromatograms from Sanger 
sequencing runs were visually inspected during assembly, 
and any chromatograms with dual peaks were excluded 
from further analysis. When multiple clones that resulted 
from a single PCR reaction were not identical, suggesting 
that more than one amplifiable template was present dur-
ing PCR amplification, only one representative clone was 
selected for further analysis.
Genetic analysis
Examination of env sequences proceeded much as has 
been described previously [93]. In brief, all chroma-
tograms from Sanger sequencing runs were visually 
inspected during assembly, and any chromatograms 
with dual peaks were excluded from further analysis. 
All sequences were compared against the HIV-1 data-
base using ViroBLAST [94] to rule out cross-contam-
ination. Sequences were aligned in MUSCLE v3.7 [95] 
and refined manually using Geneious (Biomatters, Auck-
land). A maximum likelihood tree was calculated in 
PhyML v3.0 [96] using the online tool DIVEIN (http://
indra.mullins.microbiol.washington.edu/DIVEIN/) (doi: 
10.2144/000113370), which implements the evolutionary 
model GTR + I + G. The tree was rooted with the sub-
type B reference sequence HXB2 and represented using 
FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/software/
figtree). Potential N-linked glycosylation sites (PNGs) 
were identified using the N-Glycosite tool on the LANL 
website (http://www.hiv.lanl.gov/content/sequence/GLY-
COSITE/glycosite.html) [97].
The number of founder variants establishing infection 
was inferred by detailed assessment of the infant virus 
populations, including the number of phylogenetically 
informative mutation sites (i.e., specific mutations found 
in more than one sequence, or “InSites”) as determined 
by DIVEIN; the number of observed sublineages (multi-
ple sequences sharing the same InSites) and the number 
of mutations defining the sublineage; whether insertions 
or deletions (InDels) were detected and shared across dif-
ferent sequences; whether probable recombination was 
observed; and the number of maternal sequences found 
to represent the most recent common ancestor (MRCA) 
associated with transmission. The amount of time 
between PCR-based identification of infant infection and 
virus population sampling was also considered in making 
this determination (Additional file  10: Table S1; Addi-
tional file 2: Figures S2, Additional file 3: Figure S3).
Cells and reagents
293T retroviral packaging cells were obtained from either 
the American Type Culture Collection (ATCC) or from 
Clontech (Lenti-X 293T cells), and TZM-bl cells were 
obtained through the National Institutes of Health (NIH) 
AIDS Reagent Program (catalog #8129), courtesy of Dr. 
John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. 
TZM-bl is a HeLa clone that constitutively expresses 
high surface levels of CD4, CCR5, and CXCR4 and con-
tains both luciferase and β-galactosidase reporter genes 
under control of the HIV-1 LTR promoter [98–101]. 
TZM-bl and 293T packaging cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Fisher 
Scientific) supplemented with 10% fetal bovine serum 
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(Gemini Bio-products), 100  U/mL penicillin-100  µg/µL 
streptomycin (Gibco), and 2  mM  l-glutamine (Gibco). 
GHOST-R5 (expressing CCR5) and GHOST-X4 (express-
ing CXCR4) cells were also obtained from the NIH AIDS 
Reagent Program (catalog #3944 and #3685, respectively), 
courtesy of Dr. Vineet N. KewalRamani and Dr. Dan R. 
Littman, and were maintained in DMEM with 4.5  g/L 
glucose (Fisher Scientific), 10% FBS, 500  µg/mL G418 
(Invitrogen), 100  µg/mL hygromycin (Invitrogen), and 
1 µg/mL puromycin (Sigma-Aldrich). Affinofile cells have 
been previously described [65]; briefly, these cells contain 
independently inducible CD4 and CCR5 expression con-
structs under the regulatory control of tetracycline and 
ponasterone, respectively, as well as an HIV-promoter-
driven, secreted Gaussia luciferase reporter. Affinofile 
cells were maintained in Affinofile media (AfM) con-
taining Advanced DMEM (Gibco, Carlsbad, CA) sup-
plemented with 2% dialyzed FBS (Hyclone, Waltham, 
MA), 2  mM  l-glutamine (HiMedia), 100 U/mL penicil-
lin G/100  µg/µL streptomycin (Mediatech), and 50  µg/
mL blasticidin (Mediatech). QuantiBRITE™ beads for 
flow cytometry experiments with Affinofile cells were 
purchased from BD Biosciences (catalog #340495; Frank-
lin Lakes, NJ). Phycoerythrin (PE)-conjugated mouse 
anti-human CD4 (clone RPA-T4, catalog #555347), anti-
human CCR5 (clone 2D7, catalog #555993), and isotype 
control (clone MOPC-21, catalog #555749) monoclonal 
antibodies (mAbs) with a 1:1 antibody:PE ratio were also 
purchased from BD Biosciences.
The following drugs and antibodies were obtained 
through the NIH AIDS Reagent Program: HIV-1 gp41 
mAbs 4E10 (catalog #10091) and 2F5 (catalog #1475), 
courtesy of Dr. Hermann Katinger [48–51]; HIV-1 gp120 
mAb IgG1 b12 (catalog #2640) from Drs. Dennis Bur-
ton and Carlos Barbas [54–57]; TAK-779 from Takeda 
Chemical Industries, Ltd. (catalog #4983) [60, 61]; T-20 
from Roche (catalog #9845); and sCD4-183 (catalog 
#7356) from Pharmacia, Inc. [59] The mAbs 4E10 and 
IgG1 b12 were also purchased directly from Polymun 
Scientific. The bnAbs PG9 and PG16 were kindly pro-
vided through the International AIDS Vaccine Initiative 
(IAVI), courtesy of Dr. Dennis Burton and the Protocol 
G team.
Pseudovirus production
Pseudovirus was produced by co-transfection of 293T 
cells with a plasmid containing a cloned maternal or 
infant env sequence and the pSG3∆Env backbone 
(obtained through the NIH AIDS Reagent Program; 
catalog #11051) using Fugene 6 (Roche Applied Sci-
ence). The culture medium was clarified by centrifuga-
tion at 48–72 h post-transfection, and then aliquoted and 
stored at −80 °C. One aliquot was thawed and titered on 
TZM-bl cells. The percentage of functional clones rela-
tive to the total number of clones amplified varied from 6 
to 90% among the transmission pairs.
Neutralization assays
Infectivity assays were performed in a 96-well plate for-
mat using TZM-bl cells as previously described [93]. Fifty 
percent inhibitory concentrations (IC50’s) for each tested 
inhibitor were interpolated from data points immediately 
above and below the 50% infectivity level in log-linear 
plots of dose–response curves using Excel (Microsoft). 
Each infectivity data point in the dose response curve 
represented the mean of at least two separate tests of a 
given inhibitor concentration and showed less then 30% 
variation among these tests.
Affinofile assay
On Day 0, Affinofile cells were trypsinized (TrypLE; 
Lifetech, Carlsbad, CA), washed once with AfM, counted, 
and diluted to 200,000  cells/mL prior to induction. An 
aliquot of uninduced cells treated with carrier controls 
(ethanol and deionized water) was replated, and the 
remaining cells were treated with 2 µM ponasterone (Inv-
itrogen/Life Technologies) to induce high levels of CCR5 
expression. CCR5-induced cells were then split into six 
pools for treatment with doses of doxycycline (Calbio-
chem, Billerica, MA) ranging between 0.1 and 1.6  ng/
mL to induce CD4 expression. Doxycycline-induced cells 
were plated at 20,000 cells/well in 96-well plates, with a 
small remainder reserved for culture in a T-25 flask for 
subsequent flow cytometry analysis.
On Day 1, media was aspirated from all wells and 
2000  IU virus was added to duplicate wells of a 96-well 
plate after being diluted in AfM without diethylaminoe-
thyl (DEAE)-dextran to a total volume of 200 µL, which 
yielded 10,000–20,000 relative light units (RLUs) per well 
after a 48 h incubation. AfM without virus was added to 
uninfected cell control wells. The induced and uninduced 
Affinofile cells were trypsinized in T25 flasks and washed. 
Receptor expression levels were subsequently measured 
by quantitative fluorescence-activated flow cytometry 
(qFACS) using PE-conjugated α-CD4 and α-CCR5 mAbs, 
PE-conjugated QuantiBRITE™ beads, and a LSR II flow 
cytometer (Becton–Dickinson). A standard curve gen-
erated from measurements with the QuantiBRITE™ 
beads having known PE levels allowed calculation of cell 
surface concentrations of CD4 (expressed as antibody 
binding sites (ABS)/cell), taking into account that the 
α-CD4 mAbs used in Affinofile experiments have a 1:1 
PE:antibody molar ratio.
On Day 3, 30  µL of luciferase-containing superna-
tant was transferred from wells containing infected or 
mock-infected cells to a 96-well white opaque plate and 
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read on a Lumistar Optima instrument (BMG Labtech, 
Cary, NC) using a Gaussia-luciferase kit (New England 
Biolabs, Ipswich, MA) per manufacturer’s instructions. 
RLU values were compared between duplicate wells 
and any pairs with >25% variation were discarded as 
invalid. Data from an entire sample were discarded if 
the 1.6  ng/mL doxycycline wells (high control) were 
either invalid due to unacceptable variance, or less 
than threefold higher RLU readout than the cell con-
trol well values. RLU values for each pair of wells were 
averaged and the mean cell-control value subtracted 
before normalization (as a percentage) to the 1.6  ng/
mL doxycycline RLU value for that sample. Percent 
infectivity values were then pooled across a minimum 
of three independent experiments for each sample and 
plotted in Excel (Microsoft, Redmond, WA) against 
the absolute number of CD4 molecules/cell (as deter-
mined through comparison to the QuantiBRITE™-
derived standard curve) to construct a single infectivity 
curve for each isolate across a ~100-fold range of CD4 
expression levels. Each infectivity curve was used to 
calculate the number of CD4 molecules required to 
achieve 20% of maximum entry (EC20) for a given vari-
ant. The 20% value was chosen based on an early analy-
sis of control viruses, before the bulk of the data were 
analyzed. These assay parameters consistently resulted 
in detectable, low-level viral entry and good assay-to-
assay reproducibility.
CCR5 infectivity curves were generated using the same 
protocol, except CD4 was induced to saturating levels 
with 3 ng/mL doxycycline and CCR5 levels were adjusted 
using a ponasterone concentration range of 3–0.05  µM, 
giving a 100-fold range of CCR5 surface density (approxi-
mately 100–10,000 CCR5 ABS/cell).
Median effect analysis
The median effect framework provides characterization 
of viral inhibitors through a logarithmic transformation 
of dose response curves from infection assays [66, 67], as 
described in Eq. 1:
where fa is the fraction of affected virus, D is the inhibitor 
concentration, Dm represents the inhibitor concentration 
that causes 50% of the maximum inhibitory effect (equiv-
alently, the inhibitor IC50), and m is a slope parameter 
that is analogous to the Hill coefficient [102] and pro-
vides a measure of the cooperativity of the system. The 
median effect model was fit to viral inhibition data using 
linear regression with in-house perl scripts, providing 
slope and IC50 values of a given inhibitor for each tested 
(1)log
(
fa
1− fa
)
= m log (D)−m log (Dm)
maternal and infant isolate. In all cases, median effect fits 
were determined from the average of two experimental 
replicates for each neutralization curve, and isolates for 
which the squared correlation coefficient (R2) was 0.9 or 
better were selected for further analysis. Those isolates 
that could not be neutralized by 50% within the range 
of inhibitor concentrations used in viral infection assays 
were not analyzed further.
Statistical analysis
We used GEE modeling to compare mean values of 
genotypic and phenotypic features between mother 
and infant sequences. GEE is a parametric method that 
takes into account differences in the number of isolates 
tested per patient, as well as the relatedness of linked 
maternal and infant isolates. All inhibitor IC50 datasets 
were log10-transformed prior to GEE analysis to yield 
a normal distribution, and an exchangeable correlation 
matrix was used for GEE calculations. Data analysis was 
conducted using SAS 9.1 (Cary, NC, USA) and R [103]. 
Diversity comparisons were done using the method of 
Gilbert et  al. [104], and proportion of putative multi-
variant transmissions were compared using Fisher’s 
exact test. All reported p values are based on GEE test-
ing unless otherwise specified, and were adjusted for 
multiple comparisons using the method of Benjamini 
and Hochberg to control for the false discovery rate 
[105].
Accession numbers
 Nucleotide sequences associated with this manuscript 
have been submitted to GenBank with accession num-
bers: GU939049–GU939104, GU939106, GU939107, 
GU939124–GU939142, HM036739–HM036745, HM036 
747–HM036749, HM036751–HM036789, HM036791, 
HM036793, HM036794, HM036797–HM036800, HM0 
36802–HM036831, HM036983–HM037012, HM037015–
HM037021, HM037023–HM037037 and KY229251–
KY229682. Alignments are available at: https://mullinslab.
microbiol.washington.edu/publications/nakamura_2016/.
Additional files
Additional file 1: Figure S1.Domains of the HIV-1 envelope proteins. SP, 
signal peptide; C1–C5, conserved domains; V1–V5, variable domains; ECD, 
gp41 extracellular domain; TM, gp41 transmembrane domain; CD, gp41 
cytoplasmic domain.
Additional file 2: Figure S2.Pairwise comparisons of genetic diversity 
within infant founder virus populations. All pairwise comparisons are 
shown scaled to the same genetic divergence in each panel on the X-axis, 
with bin intervals of 0.002, but with differentially scaled Y axes that reflect 
the variable number of sequences obtained from each infant.
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Additional file 3: Figure S3.Phylogenetically informative mutation sites 
and assessment of single versus multiple virus founders in infants. (a) 
Number of InSites in the infant virus founder populations and the assess-
ment of single versus multiple founders. Note that tally of these sites were 
only one of several criteria used to assess funder numbers (see Additional 
file 10: Table S1 for full list of criteria). (b, c) Phylogenetic trees and align-
ment of phylogenetically informative sites for sequences from the two 
infants in panel (a) with 6 such sites. These were the only two infants for 
which the data across all criteria were not unambiguous. While both had 
evidence of multiple variants, the presence of two founders defined by 
GGC versus AAA (the latter in the lower infant clade) was clearer in B19, 
whereas the multiple variants in B16 could have resulted from immune 
escape when sampled at 88 days of virus positivity.
Additional file 4: Figure S4.sCD4, TAK-779, PG9, and PG16 IC50 data for 
maternal- and infant-derived envelopes, presented on a pair-by-pair basis. 
(a) the IUT group and (b) the BMT group. Median IC50 values are indicated 
by a horizontal bar. Wilcoxon rank-sum tests were used to compare 
IC50 values obtained from maternal and infant isolates from a given 
maternal–infant pair, with resulting p values being corrected for multiple 
comparisons using the method of Benjamini and Hochberg [105]. Any p 
values showing a significant difference between IC50’s from the maternal- 
and infant-derived variants (p ≤ 0.05) are indicated in red.
Additional file 5: Figure S5.Representative CD4 infectivity curves 
using Affinofile cells for IUT (top) and BMT (bottom) maternal–infant pairs. 
Affinofile cells were induced to generate a 100-fold range of CD4 surface 
density (ABS/cell) and infected with 2000 IU pseudotyped virus. Percent 
infection was measured as the percent luciferase relative to infected and 
maximally induced Affinofile cells. Data shown are representative curves 
among 3–4 experimental replicates.
Additional file 6: Figure S6.Surface CCR5 molecules needed to produce 
20% of maximum infectivity (EC20), by subject and transmission type. The 
number of envelope sequences tested for each group (n) is shown. The 
grey box indicates the 95% confidence interval and the whiskers indicate 
the 99% confidence interval.
Additional file 7: Figure S7.CCR5 infectivity curves using Affinofile cells 
for IUT (top) and BMT (bottom) maternal–infant pairs. Affinofile cells were 
induced to generate a 100-fold range of CCR5 surface density (ABS/cell) 
and infected with 2000 IU pseudotyped virus. Percent infection was meas-
ured as the percent luciferase relative to infected and maximally induced 
Affinofile cells. Data shown are the average of three replicates.
Additional file 8: Figure S8.Representative PG9 neutralization curves 
for IUT (top) and BMT (bottom) maternal–infant pairs. Data shown are 
representative curves among 3–4 experimental replicates.
Additional file 9: Figure S9.Representative sCD4 neutralization curves 
for IUT (left) and BMT (right) maternal–infant pairs. Data shown are repre-
sentative curves among 3–4 experimental replicates.
Additional file 10: Table S1.Identification of founder variants establish-
ing infection. Infant infections that were inferred to be associated with 
single (S) or multiple (M) founder variants are shown, along with data 
used to make these determinations. Given the varying time between 
the first PCR-positive HIV test and virus population sampling in the 
infected infant, the wide range in the number of maternal and infant viral 
sequences sampled, and the unknown impact of early immune responses 
in selecting for mutations in the virus population, multiple criteria were 
considered when assessing whether transmission was associated with sin-
gle or multiple founder variants. These criteria included (i) the number of 
phylogenetically informative mutation sites (InSites) computed by DIVEIN 
(doi: 10.2144/000113370), (ii) the minimum number of viral sublineages 
(multiple sequences sharing the same InSites), (iii) the estimated number 
of shared mutations defining these sublineages, (iv) whether insertions or 
deletions (InDels) were detected and shared across different sequences, 
(v) whether probable recombination was observed between sequences, 
and (vi) the number of maternal sequences found to represent the most 
recent common ancestor (MRCA) of the infant’s infection in phylogenetic 
trees. Multiple founders were inferred when the infant virus population 
emerged from more than a single MRCA in the mother, and/or when 
sublineages were detected that differed by 4 or more mutations (includ-
ing InDels). Supporting these inferences were the detection of recom-
binants between sublineage sequences. The number of sublineages and 
mutations defining these sublineages were in some cases not precisely 
defined due to recombination. While in utero transmission showed a 
higher incidence of multiple founder virus outgrowth (67% in the IUT 
group versus 31% in the BMT group), our sampling was insufficient to 
determine a statistically-significant difference (p = 0.319, Fisher’s exact 
test).
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